--------------------------------------------------------------------------------
  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
--------------------------------------------------------------------------------
other/New Products/LifeWatch AG
19.12.2012


Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE),
the leading wireless remote cardiac and medical patient monitoring service
provider in the U.S., today reports the receipt of the No Objection Certificate
from the Central Drugs Standard Control Organization of the Indian Ministry of
Health & Family Welfare. LifeWatch may now export and sell the LifeWatch V
smartphone across India.

You will find a PDF-version of this press release at the end of this message.   

Shortly after being awarded the CE mark for the LifeWatch V health smartphone
platform, LifeWatch can today report another milestone for its state-of-the-art
device dedicated to health and wellness conscious consumers. The Central Drugs
and Standard Control Organization of the Indian Ministry of Health & Family
Welfare in New Dehli has granted the No Objection Certificate ("NOC") for the
LifeWatch V health smartphone. This certificate allows LifeWatch to export and
sell the device across India.      

The LifeWatch V is a fully featured state-of-the-art smartphone that allows
patients and health- and wellbeing-conscious consumers to self-operate a wide
range of embedded medical sensors, wellness-related applications, cloud-based
services and 24/7 call center support. By using the barely visible sensors on
the phone's frame, users can track, capture, collect and analyze their health
measurements anywhere anytime. The sensors include ECG, body temperature, blood
glucose, heart rate, blood oxygen saturation, body fat percentage and stress
analysis measurement. All of the collected data can be retrieved from the cloud
for a follow-up. Users can take corrective action, plan diets and activities,
securely share the information with a health provider or family member, trend
and analyze the data and more. Patients may also program the LifeWatch V to
remind them of their drug type, dose and intake time.

The LifeWatch V smartphone is an important milestone on the Company's way
towards more diversification into new service areas such as the consumer and
wellness markets and into new geographies. With the NOC certificate, LifeWatch
can enter the Indian marketplace which is considered one of the most important
future healthcare markets in the world.      

"Our receipt of the NOC is another important step in the go-to-market strategy
of the LifeWatch V smartphone, and closely follows our announcement of being
rewarded the CE mark in the beginning of December 2012", stated Dr. Yacov Geva,
Chairman of LifeWatch AG. "This latest approval demonstrates again our capacity
to develop and manufacture devices that meet commercial regulatory requirements
not only in the U.S. but also in important emerging markets like India". 


About LifeWatch AG:
                 
LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote patient
monitoring services. LifeWatch services cater to individuals, ranging from
high-risk and chronically ill patients, to consumers of health and wellness
products. LifeWatch AG has operative subsidiaries in the United States, in
Switzerland and in Israel and is the parent company of LifeWatch Services Inc.,
and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a leading US-based
provider of cardiac monitoring services and home sleep testing of Obstructive
Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is a leading
developer and manufacturer of telemedicine products. The Company is planning to
introduce the LifeWatch V, an Android-based smartphone with medical sensors and
apps that uses a cloud-based service platform. For additional information,
please visit {www.lifewatch.com}[HYPERLINK: http://www.lifewatch.com].


Sign-up for customized email alerts and documentation requests is available at
http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position,
business strategy and plans and objectives for future operations, are
forward-looking statements. The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect" and similar expressions are
intended to identify forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and projections about
future events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short term and long term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only on
data available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise. 

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE
AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN
THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES
OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED
WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN
APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES
SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED
STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH
AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION
ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE
ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/IPI4rsuU

Further inquiry note:
Sensus Communication Consultants, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email  lifewatch@sensus.ch

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/IPI4rsuU


issuer:      LifeWatch AG
             Rundbuckstrasse 6
             CH-8212 Neuhausen am Rheinfall
phone:       +41 52 632 00 50
FAX:         +41 52 632 00 51
mail:         users@lifewatch.com
WWW:      www.lifewatch.com
sector:      Healthcare Providers
ISIN:        CH0012815459
indexes:     SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
             SIX Swiss Exchange 
language:   English